Noticias y Actividades de Median Technologies
Presencia
Median Technologies es una empresa que cotiza bajo el símbolo de cotización ALMDT (FR).
Ejecutivos
Ver el organigrama con sus 10 ejecutivos principales
Biografías más buscadas en Median Technologies
- Fredrik Brag, Chief Executive Officer and Director
- Kapil Dhingra, Director
- Oran Muduroglu, Chairman of the Board
Crear su alerta
para seguir los movimientos de los ejecutivos en Median Technologies.
Salud
Median Technologies tiene 2.051 competidores entre los que se incluyen UnitedHealth Group (Estados Unidos), Siemens Healthineers (Alemania) y Optum (Estados Unidos).
Popular M&A news in Salud
- Nourish acaba de anunciar una recaudación de fondos de 70 millones de dólares. (publicado el 25 de abril de 2025).
- Accolade and Accolade have announced they will merge (publicado el 9 de abril de 2025)..
- Solace Health acaba de anunciar una recaudación de fondos de 60 millones de dólares. (publicado el 4 de abril de 2025).
Otros contactos sugeridos en el sector Salud
Noticias
Últimos comunicados de prensa de Median Technologies
- Median Technologies reports 2025 Q1 key financial indicators and provides an update on Q1 key operational achievements - Median Technologies
- Disclosure of total number of voting rights and number of shares in the capital as of March 31, 2025 - Median Technologies
- eyonis™ LCS, Median Technologies’ AI-powered Software as a Medical Device for lung cancer screening, confirmed efficacy and safety in RELIVE pivotal study - Median Technologies
- Median Technologies meets the eligibility conditions for the PEA-PME scheme - Median Technologies
- Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2025 - Median Technologies
- Median Technologies announces the availability of the preparatory documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025 - Median Technologies
- Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2025 - Median Technologies
- Median Technologies gives update on drawdowns of the Iris equity line - Median Technologies
- eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions - Median Technologies
- Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU - Median Technologies
- View more press releases Close
Redes sociales sobre Median Technologies
- Median Technologies en Wikipedia, Google News y Yahoo Finance
- Median Technologies en LinkedIn, Twitter y YouTube
